



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :C07K 15/00, G01N 33/569
A61K 39/21, 39/395, C12N 15/49

A3

(11) International Publication Number:

WO 91/09872

(43) International Publication Date:

11 July 1991 (11.07.91)

(21) International Application Number: PCT/US90/07210

(22) International Filing Date: 13 December 1990 (13.12.90)

(30) Priority data:

450,150

13 December 1989 (13.12.89) US

(71) Applicant: UNIVAX BIOLOGICS, INC. [US/US]; 12111
Parklawn Drive, Rockville, MD 20852 (US).(71)(72) Applicant and Inventor: SHAFFERMAN, Avigdor [IL/
IL]; 69 Ben Gurion Street, 70 450 Ness-Ziona (IL).(74) Agents: BENT, Stephen, A. et al.; Foley and Lardner,
Schwartz, Jeffery, Schwaab, Mack, Blumenthal, & Evans,
1800 Diagonal Road, Alexandria, VA 22313 (US).(81) Designated States: AT (European patent), AU, BE (Euro-
pean patent), CA, CH (European patent), DE (Euro-
pean patent), DK (European patent), ES (European pa-
tent), FR (European patent), GB (European patent), GR
(European patent), IT (European patent), JP, KR, LU
(European patent), NL (European patent), SE (Euro-
pean patent).**Published***With international search report.**Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*

(88) Date of publication of the international search report:

2 April 1992 (02.04.92)

(54) Title: HIV-1 ENV FRAGMENT FUSION PROTEIN

HIV88**HindIII**

AGCTT	Asn	Val	Thr	Glu	Asn	Phe	Asn	Met	Trp
A	AAC	GTA	ACT	GAA	AAC	TTC	AAC	ATG	TGG
	TTG	CAT	TGA	CTT	TTG	AAG	TTG	TAC	ACC

Lys	Asn	
AAA	AAC	CTGCA
TTT	TTG	G

PstI

(57) Abstract

Highly conserved polypeptide sequences derived from gp41 and gp 120, preferably from eleven to twenty-one amino acids in length, are joined (for example, via DNA recombinant techniques) to a non-HIV protein or polypeptide sequence comprising an amino-acid sequence not naturally encoded by the HIV genome, thereby forming a fusion protein. Such fusion proteins possess attributes that make them suitable for use in the diagnosis, treatment and prevention of HIV infection.

* (Referred to in PCT Gazette No. 08/1992, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	Chemical Abstracts, volume 111, no. 9, 28 August 1989, (Columbus, Ohio, US), Shafferman, Avigdor et al.: "Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stages of HIV infection", see page 576, abstract 76027v, & AIDS Res. Hum. Retroviruses 1989, 5(1), 33- 39	1-7
Y	--	1-7, 8, 15-17
Y	Dialog Informational Service, File 157: AIDSLINE accession no. 06475126, Lenz, A et al: "Serologic AIDS diagnosis with polypeptides obtained by genetic technics of the human immunodeficiency virus (HIV-1) A", & Klin Wochenschr Nov 2 1987, 68 (21) p1042-7	1-7
A	WO, A1, 8909393 (IGEN, INCORPORATED) 5 October 1989, see page 5, line 21 - line 31 example 5	1
A	Nature Vol., vol. 329, 1987, S. E. Adams et al.: "The expression of hybrid HIV:Ty virus-like particles in yeast ", see page 68 - page 70	1, 8, 15
Y	EP, A2, 0305777 (BEHRINGWERKE) 8 March 1989, see page 4, line 20 - page 8	8, 15-17
A	EP, A2, 0345792 (F HOFFMANN-LA ROCHE AG) 13 December 1989, see page 7 - page 10; claims 1-3	1
Y	EP, A2, 0227169 (AKZO N.V.) 1 July 1987, see page 5; figures 7, 10, 11b; claims 18, 20, 29, 30	1-8, 15-17

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 90/07210

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 K 15/00, G 01 N 33/569, A 61 K 39/21, 39/395 C 12 N 15/49		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC5	C 07 K; G 01 N; A 61 K	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	WO, A2, 8902277 (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) 23 March 1989, see page 11, line 32, table 1, blocks no 61-63, page 23, lines 16-20 and claims 3-4	1-4, 8, 15-17
--		
X	WO, A1, 8602383 (INSTITUT PASTEUR) 24 April 1986, see page 26, line - page 30, line; page 39, line 16 - page 40, line 16; page , line ; claims 7-8	1-2, 4, 8
Y		1-8, 15-17
--		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"S" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
23rd April 1991	13 JAN 1992	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	<div style="display: flex; align-items: center;"> <div style="flex: 1;">Mme N. KUIPER</div> <div style="flex: 1; text-align: right;"> </div> </div>	

Form PCT/ISA/210 (second sheet) (January 1983)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	Chemical Abstracts, volume 107, no. 55, 3 August 1987, (Columbus, Ohio, US), Palker, Thomas J. et al.: "A conserved region at the carboxy terminus of human immunodeficiency virus gp 120 envelope protein contains an immunodominant epitope", see page 514, abstract 37664y, & Proc.Natl.Acid.Sci. 1987, 84(8), 2479-2483 --	1-4,8, 15-17
X	WO, A1, 8606414 (GENETIC SYSTEMS CORPORATION) 6 November 1986, see pages 10-11, peptides 39, 36 and 50, pages 17-21 and claims	1,2,8
Y	--	1-8,15- 17
X	Chemical Abstracts, volume 113, no. 21, 19 November 1990, (Columbus, Ohio, US), Hunt, J. C. et al.: "Mouse monoclonal antibody 5-21-3 recognizes a contiguous, conformation-dependent epitope and maps to a hydrophilic region in HIV-1 gp41", see page 529, abstract 189272f, & AIDS Res. Hum. Retroviruses 1990, 62(5), 587-598	15-17
Y	--	1-4,8, 15-17
X	EP, A2, 0335134 (ABBOTT LABORATORIES) 4 October 1989, see page 14, line 6 - line 12; page 19 - page 20	15-17
Y	--	1-4,8
X	EP, A2, 0362909 (AKZO N.V.) 11 April 1990, see column 4, line 32 - line 52; figure 1; claim 1	1,15- 17
X	WO, A1, 8808005 (JOHNSON AND JOHNSON) 20 October 1988, see table 8 (page 63), peptides XII and IV, pages 19-25, page 12, line 20-23	1,5,6
Y	--	1-8,15- 17

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	EP, A2, 0330359 (BIO-RAD LABORATORIES, INC.) 30 August 1989, see page 5, peptide 88, page 6, peptide 105, page 8, line 58 - page 9 and claim 1	1,8,15- 17
Y	--	1-4,8, 15-17
Y	AIDS, vol. 3, 1989, Dani P. Bolognesi: "HIV antibodies and vaccine design", see page 111 - page 118 see the whole document and in particular fig. 1	8,15- 17
Y	EP, A2, 231914 (F. HOFFMANN-LA ROCHE & CO.) 12 August 1987, see claim 1 and examples	1-4,8, 15-17
Y	Chemical Abstracts, volume 110, no. 19, 8 May 1989, (Columbus, Ohio, US), see page 639, abstract 171673r, & US, A, 874913 (Synthetic peptides and antibodies for diagnosis of AIDS and for vaccines) 15 April 1988	1-4,8, 15-17
Y	WO, A1, 8702775 (SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH) 7 May 1987, see peptide 3 in table II, claims 12 and 20	1-4,8, 15-17
Y	WO, A1, 8800471 (SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH) 28 January 1988, see table II (page 27), peptides 6 and 9, example 5 and claims	1-4,8, 15-17
Y	Chemical Abstracts, volume 111, no. 15, 9 October 1989, (Columbus, Ohio, US), Ruegg, Curtis L et al.: "Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1", see page 602, abstract 132340f, & Virol. 1989, 63(8), 3257-3260	1-4,8, 15-17

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	<p>Chemical Abstracts, volume 109, no. 17, 24 October 1988, (Columbus, Ohio, US), Klasse, Per Johan et al.: "Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects", see page 560, abstract 147593y, & Proc. Natl. Acad. Sci.</p> <p>--</p>	1-8,15-17
A	<p>Chemical Abstracts, volume 107, no. 25, 21 December 1987, (Columbus, Ohio, US), Gnann, John W., Jr. et al.: "Diagnosis of AIDS by using a 12-amino acid peptiderepresenting an immunodominant epitope of the human immunodeficiency virus", see page 590, abstract 234358c, & J. Infect. Dis. 1987, 156(2), 261- 267</p> <p>--</p> <p>-----</p>	1,5-7

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Chemical Abstracts, volume 105, no. 21, 24 November 1986, (Columbus, Ohio, US), Wang, James J. G. et al.: "Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein", see page 543, abstract 188911m, & Proc.Natl.Acad.Sci. 1986, 83(16), --	1-8,15-17
Y	EP, A2, 0214709 (UNITED BIOMEDICAL INC.) 18 March 1987, see table VI, peptides 6-8, claims and page --	1-3,5-8
Y	WO, A1, 8706005 (ORTHO PHARMACEUTICAL CORPORATION) 8 October 1987, see page 7 peptides IV and XII, table V and claims 1, 5, 13, 24 --	1-3,5-8, 15-17
A	EP, A2, 0251612 (GENETIC SYSTEMS CORPORATION) 7 January 1988, see pages 7-11, peptides 39 and 79 --	1-3,5-7, 15-17
Y	WO, A1, 8903844 (FERRING AB) 5 May 1989, see page 6, line 31 - line 36; page 8, line 29 - page 10, line 19 example III --	1-8,15-17
A	Chemical Abstracts, volume 112, no. 11, 12 March 1990, (Columbus, Ohio, US), Norrby, Erling et al.: "The chemistry of site-directed serology for HIV infections", see page 591, abstract 96724u, & AIDS Res. Hum. Retroviruses 1989, 5(5), 487- 493 --	1,5-8

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/US 90/07210**

SA 43308

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 31/10/91. The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A2- 8902277	23/03/89	AU-D- 2914889	17/04/89
WO-A1- 8602383	24/04/86	AU-D- 5061785	02/05/86
		EP-A-B- 0201540	20/11/86
		EP-A- 0387914	19/09/90
		EP-A- 0387915	19/09/90
		FR-A-B- 2571968	25/04/86
		JP-T- 62500592	12/03/87
		AU-B- 603543	22/11/90
		AU-B- 600227	09/08/90
		AU-D- 5320086	13/08/86
		EP-A-B- 0211022	25/02/87
		JP-T- 62502095	20/08/87
		OA-A- 8413	30/06/88
		WO-A- 86/04336	31/07/86
WO-A1- 8909393	05/10/89	AU-D- 3342689	16/10/89
EP-A2- 0305777	08/03/89	AU-D- 2065488	23/03/89
		DE-A- 3727137	23/02/89
		JP-A- 1071488	16/03/89
EP-A2- 0345792	13/12/89	AU-D- 3625589	14/12/89
		JP-A- 2042987	13/02/90
EP-A2- 0227169	01/07/87	AU-B- 612315	11/07/91
		AU-D- 6651986	02/07/87
		JP-A- 62240863	21/10/87
EP-A2- 030359	30/08/89	NONE	
EP-A2- 231914	12/08/87	NONE	
WO-A1- 8702775	07/05/87	EP-A- 0245362	19/11/87
		JP-T- 63501716	14/07/88
		US-A- 4956273	11/09/90
WO-A1- 8800471	28/01/88	AU-D- 7786387	10/02/88
		EP-A- 0276279	03/08/88
		JP-T- 1500432	16/02/89
WO-A1- 8606414	06/11/86	AU-B- 571128	31/03/88
		AU-B- 597884	14/06/90
		AU-D- 5572786	16/10/86

For more details about this annex : see Official Journal of the European patent Office, No. 12/82

EPO FORM P0479

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers...9-13 because they relate to subject matter not required to be searched by this Authority, namely:

see PCT Rule 39.1 (iv)

Method for treatment of the human or animal body by means of surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

- A. Claims: 1-4,8,14-17 (partially) See Form PCT/ISA 206 dated
B. Claims: 1-4,8,14-17 (partially) 16th July 1991
C. Claims 1-8,14-17 (partially)
D. Claims 1-4,8,14-17 (partially)

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the the claims. It is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☒ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/US 90/07210

SA 43308

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 31/10/91. The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 8606414	06/11/86	AU-D- 5773386	18/11/86
		EP-A- 0201716	20/11/86
		EP-A- 0220273	06/05/87
		JP-T- 62502617	08/10/87
		US-A- 4629783	16/12/86
		US-A- 4768607	06/09/88
EP-A2- 0335134	04/10/89	AU-D- 3021989	05/10/89
		JP-A- 2119794	07/05/90
EP-A2- 0362909	11/04/90	AU-D- 4080189	01/03/90
		JP-A- 2111791	24/04/90
WO-A1- 8808005	20/10/88	AU-D- 1702288	04/11/88
		EP-A- 0309566	05/04/89
EP-A2- 0214709	18/03/87	AU-B- 579467	24/11/88
		AU-D- 5680386	16/04/87
		JP-A- 62061996	18/03/87
		US-A- 4735896	05/04/88
		US-A- 4879212	07/11/89
WO-A1- 8706005	08/10/87	AU-D- 7234387	20/10/87
		EP-A- 0261224	30/03/88
		JP-T- 63502904	27/10/88
EP-A2- 0251612	07/01/88	AU-D- 7451287	24/12/87
		JP-A- 63107998	12/05/88
WO-A1- 8903844	05/05/89	AU-D- 2624288	23/05/89
		EP-A- 0396559	14/11/90
		JP-T- 3500648	14/02/91
		SE-A- 8704185	29/04/89

For more details about this annex : see Official Journal of the European patent Office, No. 12/82

EPO FORM P0479

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 15/00, G01N 33/569 A61K 39/21, 39/395, C12N 15/49	A2	(11) International Publication Number: WO 91/09872 (43) International Publication Date: 11 July 1991 (11.07.91)
--	----	--

(21) International Application Number: PCT/US90/07210

(22) International Filing Date: 13 December 1990 (13.12.90)

(30) Priority data:
450,150 13 December 1989 (13.12.89) US(71) Applicant: UNIVAX BIOLOGICS, INC. [US/US]; 12111
Parklawn Drive, Rockville, MD 20852 (US).(71)(72) Applicant and Inventor: SHAFFERMAN, Avigdor [IL/
IL]; 69 Ben Gurion Street, 70 450 Ness-Ziona (IL).(74) Agents: BENT, Stephen, A. et al.; Foley and Lardner,
Schwartz, Jeffery, Schwaab, Mack, Blumenthal, & Evans,
1800 Diagonal Road, Alexandria, VA 22313 (US).(81) Designated States: AT (European patent), AU, BE (Euro-
pean patent), CA, CH (European patent), DE (Euro-
pean patent), DK (European patent), ES (European pa-
tent), FR (European patent), GB (European patent), GR
(European patent), IT (European patent), JP, KR, LU
(European patent), NL (European patent), SE (Euro-
pean patent).**Published***Without international search report and to be republished
upon receipt of that report.*(54) Title: POLYPEPTIDES SELECTIVELY REACTIVE WITH ANTIBODIES AGAINST HUMAN IMMUNODEFI-
CIENCY VIRUS AND VACCINES COMPRISING THE POLYPEPTIDES**HIV88****HindIII**

AGCTT	Asn	Val	Thr	Glu	Asn	Phe	Asn	Met	Trp
A	AAC	GTA	ACT	GAA	AAC	TTC	AAC	ATG	TGG
	TTG	CAT	TGA	CTT	TTG	AAG	TTG	TAC	ACC

Lys	Asn
AAA	AAC
TTT	TTG
	CTGCA
	G

PstI**(57) Abstract**

Highly conserved polypeptide sequences derived from gp41 and gp 120, preferably from eleven to twenty-one amino acids in length, are joined (for example, via DNA recombinant techniques) to a non-HIV protein or polypeptide sequence comprising an amino-acid sequence not naturally encoded by the HIV genome, thereby forming a fusion protein. Such fusion proteins possess attributes that make them suitable for use in the diagnosis, treatment and prevention of HIV infection.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

POLYPEPTIDES SELECTIVELY REACTIVE WITH
ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS
AND VACCINES COMPRISING THE POLYPEPTIDES

Background of the Invention

5 This invention was made in part with U.S.
Government Support under Contract No. DAMD17-87-C-
7156 awarded by the United States Army Medical
Research and Development Command to the National
Research Council. The U.S. Government has certain
10 rights in this invention.

 The present invention relates to the
production and use, in diagnosis, treatment and
prevention of HIV infection, of an antigenic protein
that reacts specifically with antibodies against the
15 Human Immunodeficiency Virus type 1 (HIV-1). The
present invention also relates to a self-
replicating cell that produces such a recombinant
protein; to a vaccine comprising the recombinant
protein; to an antigen-based screening test, based
20 on the protein, for detecting antibodies to HIV; to
monoclonal and polyclonal antibodies, produced using
the protein, that protect against HIV-1 infection or
disease; and to an antibody-based screening test.

 HIV has been established as the primary
25 etiologic agent in pathogenesis of acquired

immunodeficiency syndrome (AIDS) and related disorders. See, e.g., Gruest, J., et al., Science 220: 863-71 (1983); Gallo, R.C., et al., Science 224: 500-03 (1984). Because AIDS can be transmitted by blood products, a highly accurate method of screening blood samples for presence of the virus is desirable. Infection of humans with HIV leads to production of antibodies directed against most of the viral structural antigens, forming the basis for screening via viral lysate based tests. However, these tests have several disadvantages, including false positives thought to arise from the presence of non-viral proteins in the viral lysate preparations used in the solid phase component of the current assays.

The antibodies produced upon infection include antibodies against both core and envelope proteins. The emergence of antibodies to envelope glycoproteins, e.g., gp160, and its subunits gp120 (the extracellular glycoprotein or EGP) and gp41 (the transmembrane protein or TMP), appears to precede the emergence of antibodies to core proteins, leading researchers to study these proteins as a possible basis for improved diagnostic assays. In addition, these antibodies to env proteins appear to be involved in induction of active immunity, suggesting their use in vaccine preparation.

Based on study of the envelope amino acid sequences, and in an attempt to reduce the rate of false positives, the art has proposed serological

assays employing synthetic polypeptides that mimic naturally occurring antigenic determinants on viral proteins. Data generated in studies using synthetic peptides have indicated that some of the conserved domains in gp120 and gp41, respectively, contain immunodominant epitopes that may be appropriate for diagnosis. From analysis of conserved HIV domains from gp41 it appears that, within a linear sequence spanning about 40 amino acids (amino acid 570-612), numerous and highly immunodominant epitopes of HIV reside. Wang, J.J.G., et al., Proc. Nat'l Acad. Sci. USA 83: 6159-63 (1986); Gnann, J.W., et al., J. Infect. Dis. 156: 261-67 (1987).

Conserved domains in gp120 and gp41 have also been identified that are involved in neutralization of different HIV isolates. Ho, D.D., et al., J. Virol. 61: 2024-28 (1987); Science 239: 1021-23 (1988). Neutralizing-specific antibodies to the major envelope glycoprotein are type-specific and have recently been mapped to a highly variable sequence of gp120. Putney, S.D., et al., J. Cell. Biochem. 12B: 5 (1988). Neutralization assays with immune sera from animals or humans, see Robert-Guroff, M., et al., Nature 316: 72-74 (1985); Weiss, R.A., et al., Nature 316: 69-71 (1985); Rasheed, S., et al., Virology 150: 1-6 (1986), have revealed that the envelope proteins contains epitopes that elicit antibodies capable of neutralizing HIV in vitro. But the presence of these antibodies in vivo has only a limited effect on progression of the disease, Robert-Guroff, M., et al., loc. cit.; Wendler, I.,

et al., AIDS Res. Human Retroviruses 3: 157-63 (1987), and no significant difference in titers which can be correlated with clinical status. In humans, there are no known patterns of antibody response indicative of immunity.

Summary of the Invention

It is therefore an object of the present invention to provide a fusion protein, readily produced in commercially significant quantities, that is an effective vaccine for prevention of HIV infection.

It is a further object of the present invention to provide a fusion protein, readily produced in commercially significant quantities, that is an exceedingly sensitive and specific antigen for detection of HIV-1 antibodies.

It is yet another object of the present invention to provide a highly accurate diagnostic assay for detecting antibodies to HIV-1.

In accomplishing these and other objects, there has been provided, according to one aspect of the present invention, a fusion protein comprised of an amino acid sequence selected from the group consisting of NVTENFNMWKN, KAKRRVVQREKRAVG, ERYLKDQQLLGIWGCSGKLIC and EESQNQQEKNEQELLELDKWA; and a non-HIV polypeptide sequence, such that the amino-acid sequence and the polypeptide sequence comprise the backbone of the fusion protein, wherein the fusion protein reacts with an HIV-positive serum.

In a preferred embodiment, the amino-acid sequence is joined via a peptide bond to an N-terminus of the non-HIV polypeptide sequence.

5 In accordance with another aspect of the present invention, a self-replicating cell is provided that expresses a polypeptide comprising an amino-acid sequence selected from the group consisting of NVTENFNMWKN, KAKRRVVQREKRAVG, ERYLKDQQLLGIWGCSGKLIC and EESQNQQEKNEQELLELDKWA.

10 Also provided, according to still another aspect of the present invention, is a diagnostic assay for detecting the presence of anti-HIV antibody in a sample, comprising the steps of (A) immobilizing on a solid matrix a fusion protein
15 comprising an amino-acid sequence, ERYLKDQQLLGIWGCSGKLIC and a non-HIV polypeptide sequence, such that the amino-acid sequence is accessible to an antibody contacting a surface of the matrix; (B) bringing a sample into contact with
20 the surface of the matrix; and (C) monitoring the surface for binding of HIV-specific antibody. In one preferred embodiment, step (C) comprises detecting the presence of anti-HIV antibody in a sample that tests HIV-negative when tested using a
25 conventional whole-virus western blot assay.

Pursuant to another aspect of the present invention, a diagnostic assay is provided for detecting the presence of anti-HIV antibody in a sample, comprising the steps of (A) providing a
30 fusion protein comprising an amino-acid sequence ERYLKDQQLLGIWGCSGKLIC and an amino acid sequence of

an enzyme; (B) combining a sample with the fusion protein in a liquid; and (C) monitoring the combination for a modulation of activity of the enzyme.

5

A vaccine comprising a fusion protein, as described above, and a sterile, pharmacologically acceptable carrier therefor is also provided, in accordance with yet another aspect of the present invention.

10

In accordance with another aspect of the present invention, there has been provided an immunotherapy method that comprises the step of administering to a subject an immunostimulatory amount of a vaccine as described above. In a preferred embodiment, the subject is already infected with HIV-1 when the vaccine is administered.

15

20

Pursuant to another aspect of the present invention, an immunotherapy method is provided comprising the step of administering to a subject an immunostimulatory amount of a hyperimmune globulin prepared according to a method comprised of immunizing a plasma donor with a vaccine as described above, such that a hyperimmune globulin is produced which contains antibodies directed against HIV-1. According to another aspect of the present invention, an immunotherapy method is provided that comprises administering to a subject an immunostimulatory amount of a hyperimmune globulin prepared in the aforementioned manner.

25

30

Also provided is an immunotoxin conjugate comprising a fusion protein, as described above, conjugated to an immunotoxin. In addition, an immunotherapy method is provided, according to another aspect of the present invention, wherein a subject already infected with HIV-1 receives antibodies directed against a fusion protein of the invention, wherein the antibodies are conjugated to an immunotoxin.

According to still another aspect of the present invention, a composition is provided that consists essentially of antibodies that bind the aforementioned fusion protein. (In this context, the qualifier "consists essentially of" means that the composition may have other constituents, such as a pharmaceutically acceptable carrier for the antibodies, but that the salient properties of the composition are determined by the immunological characteristics of the antibodies.) In a preferred embodiment, the composition is a monoclonal antibody composition, while in another preferred embodiment the antibodies are not obtained by a process comprising the step of providing a biological sample from a human subject infected with HIV-1.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and

modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

Brief Description of the Drawings

5 Figure 1 shows the oligonucleotide sequences coding for HIV88 (Fig. 1A), HIV500 (Fig. 1B), HIV582 (Fig. 1C) and HIV647 (Fig. 1D).

10 Figure 2 shows the oligonucleotide sequences coding for SIV88 (Fig. 2A), SIV500 (Fig. 2B), SIV582 (Fig. 2C) and SIV647 (Fig. 2D). In both Figures 1 and 2, the encoded amino acids for the respective polypeptides are also shown, as are the recognition sites for restriction endonucleases, denoted above each site, which can be used to obtain the
15 oligonucleotide sequences from the HIV-1 genome.

Description of the Preferred Embodiments

20 It has been discovered that certain short, highly conserved polypeptide sequences of gp41 and gp120, having from eleven to twenty-one amino acids, possess attributes making them suitable for use in the diagnosis, treatment and prevention of HIV infection. According to the present invention, these polypeptide sequences are joined, preferably
25 via DNA recombinant techniques, to a non-HIV protein or polypeptide sequence comprising a sequence of amino acids not naturally found in the HIV genome, to form a fusion protein.

Fusion proteins comprising these sequences have been shown to be good candidates for an HIV vaccine. While vaccines comprising these sequences have not been tested in humans, for obvious reasons, their utility in this regard is indicated by results obtained when equivalent sequences derived from SIVmac env are used to immunize Rhesus monkeys, discussed more fully below. The HIV sequences according to the invention are denominated HIV88, HIV500, HIV582 and HIV647, and have the following amino acid sequences:

HIV88:

Asn-Val-Thr-Glu-Asn-Phe-Asn-Met-Trp-Lys-Asn
(NVTENFNMWKN)

HIV500:

Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-Ala-Val-Gly (KAKRRVVQREKRAVG)

HIV582:

Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys
(ERYLKDQQLLGIWGCSGKLIC)

HIV647:

Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala
(EESQNQQEKNEQEELLELDKWA)

One of these polypeptide sequences, HIV582, combines aspects of two previously delineated immunodominant epitopes of gp41 (RILAVERYLKDQQLLGIWGCS and LGIWGCSGKLIC), and can be incorporated into fusion proteins that are

consequently recognized by virtually all HIV-positive sera. Surprisingly, it can be used to detect the presence of HIV-1-specific antibodies in sera that are obtained from patients recently infected by the virus and that test negative via whole-virus HIV-1 western blot and other conventional assays.

The identity of the non-HIV polypeptide to which the HIV polypeptide sequence is fused to form a fusion protein is not critical, but it preferably is one that can be expressed by a genetically-engineered microbe and purified from the culture medium. Exemplary of this group of polypeptides is β -galactosidase, protein G, acetylchloramphenicol transferase, tryptophan synthetase, influenza A nonstructural protein (NS1), hepatitis core and surface antigens, and bacterial exotoxins such as E. coli LT, cholera toxin, and Pseudomonas toxin A. Particularly preferred are non-HIV polypeptides that possess an enzymatic property that can be exploited for purification and/or diagnostic purposes. Enzyme activity permits easier monitoring of purification. In addition, polypeptides according to the present invention in which the HIV582 is fused to an enzyme can form the basis for a simplified diagnostic assay using a homogenous system in which modulation of enzyme activity is monitored.

β -galactosidase is particularly preferred as the non-HIV polypeptide fused to the HIV polypeptide sequence for other reasons. In addition to the advantages arising the fact that it is an enzyme, it

possesses other beneficial attributes. Since it is a tetramer it can hold four epitopes. Another significant advantage, and one that is entirely unexpected, is the fact that most people do not have any antibodies to β -galactosidase.

When an HIV polypeptide sequence is fused to β -galactosidase, the β -galactosidase acts as an immunocarrier, i.e., a substance, usually a polypeptide or protein, which is critical for the efficient interaction between T and B cells for the induction of an immune response against a small antigen that is attached to it.

A fusion protein within the present invention incorporates the HIV polypeptide sequence into the primary structure ("backbone") of the protein. It is preferred that the HIV polypeptide sequence be joined, via a peptide bond between the terminal carboxyl group of the HIV sequence and the terminal amino group of the non-HIV polypeptide. This arrangement enhances the possibility of a reaction between the fusion protein and antibodies that develop as a consequence of HIV-1 infection. Moreover, the arrangement is efficient in inducing an immune response that is specific for HIV-1.

The fusion proteins of the present invention can be produced by conventional genetic-engineering techniques. In this regard, a polynucleotide molecule encoding the desired protein preferably comprises a nucleotide sequence, corresponding to one of the amino-acid sequences according to the invention, that is optimized for the host of choice,

such as E. coli, in terms of codon usage and initiation of translation. In the same vein, the vector selected for transforming the host organism with the polynucleotide molecule should allow for efficient maintenance and transcription of the sequence coding for the fusion protein.

Fusion proteins comprising HIV582 are particularly useful in various immunoassays which detect the presence of antibodies indicative of a particular disease state. For example, western blot and ELISA immobilize the polypeptides on a solid matrix and then contact the immobilized polypeptide with a sample.

The acronym ELISA refers to "enzyme-linked immunosorbent assay," that is, an assay using an antigen or antibody bound to a solid phase and an enzyme-antibody or enzyme-antigen conjugate to detect and/or quantify antibody or antigen present in a sample. In western blot assays, solubilized and separated antigens are bound to nitrocellulose paper. The antibody is detected by an enzyme or label-conjugated anti-immunoglobulin (Ig), such as horseradish peroxidase-Ig conjugate and detected by incubating the filter paper in the presence of a precipitable or detectable substrate. Western blot assays have the advantage of not requiring purity greater than 50% for the desired polypeptide. Descriptions of the ELISA and western blot techniques are found in Chapters 10 and 11 of Ausubel, et al. (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley and Sons (1988), the

contents of which are hereby incorporated by reference.

The present invention also relates to the use of a fusion protein to produce antisera or monoclonal antibodies (mouse or human) that bind to or neutralize virus. These antibodies can be employed to produce immunotoxin conjugates (e.g., with a ricin A chain) which should be useful in therapy of HIV-1 infections. Protocols for producing these antibodies are described in Ausubel, et al. (eds.) loc. cit., Chapter 11; in METHODS OF HYBRIDOMA FORMATION 257-71, Barta & Hirshaut (eds.), Humana Press, Clifton, NJ (1988); in Vitetta et al., Immunol. Rev. 62: 159-83 (1982); and in Raso, Immunol. Rev. 62: 93-117 (1982).

Inocula for polyclonal antibody production are typically prepared by dispersing the dried solid HIV sequence-immunocarrier in a physiologically tolerable diluent such as saline to form an aqueous composition. An immunostimulatory amount of inoculum is administered to a mammal and the inoculated mammal is then maintained for a time period sufficient for the HIV sequence to induce protecting anti-HIV-1 antibodies.

Antibodies can include antiserum preparations from a variety of commonly used animals, e.g., goats, primates, donkeys, swine, rabbits, horses, hens, guinea pigs, rats or mice, and even human antisera after appropriate selection and purification. The animal antisera are raised by inoculating the animals with an immunogenic form of

the pathogen or its antigen, by conventional methods, bleeding the animals and recovering serum or an immunoglobulin-containing serum fraction.

5 The antibodies induced in this fashion can be harvested and isolated to the extent desired by well known techniques, such as by immunoaffinity chromatography; that is, by binding antigen to a chromatographic column packing like Sephadex®,
10 passing the antiserum through the column, thereby retaining specific antibodies and separating out other immunoglobulins and contaminants, and then recovering purified antibodies by elution with a chaotropic agent, optionally followed by further purification, for example, by passage through a
15 column of bound blood group antigens or other non-pathogen species. This procedure may be preferred when isolating the desired antibodies from the serum of patients having developed an antibody titer against the pathogen in question, thus assuring the
20 retention of antibodies that are capable of binding to exposed epitopes. They can then be used in preparations for passive immunization against HIV-1 or in diagnostic assays.

25 A monoclonal antibody composition contains, within detectable limits, only one species of antibody combining site capable of effectively binding HIV-1 TMP. In particular, a monoclonal antibody composition of the present invention typically displays a single binding affinity for
30 HIV-1 TMP even though it may contain antibodies capable of binding proteins other than HIV-1 TMP.

Suitable antibodies in monoclonal form can be prepared using conventional hybridoma technology. To form a hybridoma from which a monoclonal antibody composition of the present invention is produced, a
5 myeloma or other self-perpetuating cell line is fused with lymphocytes obtained from peripheral blood, lymph nodes or the spleen of a mammal hyperimmunized with a polypeptide of this invention. It is preferred that the myeloma cell line be from
10 the same species as the lymphocytes. Splenocytes are typically fused with myeloma cells using polyethylene glycol 1500. Fused hybrids are selected by their sensitivity to HAT. Hybridomas secreting the antibody molecules of this invention
15 can be identified using an ELISA.

A Balb/C mouse spleen, human peripheral blood, lymph nodes or splenocytes are the preferred materials for use in preparing murine or human hybridomas. Suitable mouse myelomas for use in the
20 present invention include the hypoxanthine-aminopterin-thymidine-sensitive (HAT) cell lines P3X63-Ag8.653 and Sp2/0-Ag14, available from the American Type Culture Collection, Rockville, MD, under the designations CRL 1580 and CRL 1581,
25 respectively. The preferred fusion partner for human monoclonal antibody production is SHM-D33, a heteromyeloma available from ATCC, Rockville, Md. under the designation CRL 1668.

A monoclonal antibody composition of the
30 present invention can be produced by initiating a monoclonal hybridoma culture comprising a nutrient

medium containing a hybridoma that secretes antibody molecules of the appropriate polypeptide specificity. The culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The antibody-containing medium is then collected. The antibody molecules can then be further isolated by well known techniques.

Media useful for the preparation of these compositions are both well known in the art and commercially available and include synthetic culture media, inbred mice and the like. An exemplary synthetic medium is Dulbecco's Minimal essential medium supplemented with 4.5 g/l glucose, 20 mm glutamine, and 20% fetal calf serum. An exemplary inbred mouse strain is the Balb/c.

Other methods of preparing monoclonal antibody compositions are also contemplated, such as interspecies fusions and genetic engineering manipulations of hypervariable regions, since it is primarily the antigen specificity of the antibodies that affects their utility in the present invention. Human lymphocytes obtained from HIV-infected individuals can be fused with a human myeloma cell line to produce hybridomas which can be screened for the production of antibodies that recognize a fusion protein of the present invention. More preferable in this regard, however, is a process that does not entail the use of a biological sample from a human subject infected with HIV-1. For example, a subject immunized with a vaccine as described herein can

serve as a source for antibodies suitably used in an antibody composition within the present invention.

The monoclonal and polyclonal antibody compositions produced according to the present description can be used to induce an immune response for the prevention or treatment of HIV infection. They can also be used in diagnostic assays where formation of an HIV-1 TMP-containing immunoreaction product is desired.

In this regard, the antibody component can be polyspecific, that is, it can include a plurality of antibodies that bind to a plurality of epitopes represented by the various conserved polypeptide sequences described above. The polyspecific antibody component can be a polyclonal antiserum, preferably affinity purified, from an animal which has been challenged with a fusion protein of the present invention and, hence, stimulated to produce a plurality of specific antibodies against the fusion protein. Another alternative is to use an "engineered polyclonal" mixture, which is a mixture of monoclonal antibodies with a defined range of epitopic specificities.

In both types of polyclonal mixtures, it can be advantageous to link polyspecific antibodies together chemically to form a single polyspecific molecule capable of binding to any of several epitopes. One way of effecting such a linkage is to make bivalent $F(ab')_2$ hybrid fragments by mixing two different $F(ab')_2$ fragments produced, e.g., by pepsin digestion of two different antibodies,

reductive cleavage to form a mixture of Fab' fragments, followed by oxidative reformation of the disulfide linkages to produce a mixture of F(ab')₂ fragments including hybrid fragments containing a Fab' portion specific to each of the original antigens. Methods of preparing such hybrid antibody fragments are disclosed in Feteanu, LABELED ANTIBODIES IN BIOLOGY AND MEDICINE 321-23, McGraw-Hill Int'l Book Co. (1978); Nisonoff, et al., Arch Biochem. Biophys. 93: 470 (1961); and Hammerling, et al., J. Exp. Med. 128: 1461 (1968); and in U.S. patent No. 4,331,647.

Other methods are known in the art to make bivalent fragments that are entirely heterospecific, e.g., use of bifunctional linkers to join cleaved fragments. Recombinant molecules are known that incorporate the light and heavy chains of an antibody, e.g., according to the method of Boss et al., U.S. patent No. 4,816,397. Analogous methods of producing recombinant or synthetic binding molecules having the characteristics of antibodies are included in the present invention. More than two different monospecific antibodies or antibody fragments can be linked using various linkers known in the art.

An antibody component produced in accordance with the present invention can include whole antibodies, antibody fragments, or subfragments. Antibodies can be whole immunoglobulin (IgG) of any class, e.g., IgG, IgM, IgA, IgD, IgE, chimeric antibodies or hybrid antibodies with dual or

multiple antigen or epitope specificities, or fragments, e.g., F(ab')₂, Fab', Fab and the like, including hybrid fragments, and additionally includes any immunoglobulin or any natural, 5 synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex. In particular, Fab molecules can be expressed and assembled in a genetically transformed host like E. coli. A lambda 10 vector system is available thus to express a population of Fab's with a potential diversity equal to or exceeding that of subject generating the predecessor antibody. See Huse, W.D., et al., Science 246: 1275-81 (1989), the contents of which 15 are hereby incorporated by reference.

A polypeptide according to the present invention can be the active ingredient in a composition, further comprising a pharmaceutically acceptable carrier for the active ingredient, which 20 can be used as a vaccine to induce a cellular immune response and/or production in vivo of antibodies which combat HIV-1 infection. In this regard, a pharmaceutically acceptable carrier is a material that can be used as a vehicle for administering a 25 medicament because the material is inert or otherwise medically acceptable, as well as compatible with the polypeptide active agent, in the context of vaccine administration. In addition to a suitable excipient, a pharmaceutically acceptable 30 carrier can contain conventional vaccine additives

like diluents, adjuvants, antioxidants, preservatives and solubilizing agents.

Pursuant to the present invention, such a vaccine can be administered to a subject not already infected with the virus, thereby to induce an HIV-protective immune response (humoral or cellular) in that subject. Alternatively, a vaccine within the present invention can be administered to a subject in which HIV-1 infection has already occurred but is at a sufficiently early stage that anti-HIV antibodies produced in response to the vaccine effectively inhibit further spread of infection.

By another approach, a vaccine of the present invention can be administered to a subject who then acts as a source for globulin, produced in response to challenge from the specific vaccine ("hyperimmune globulin"), that contains antibodies directed against HIV-1. A subject thus treated would donate plasma from which hyperimmune globulin would then be obtained, via conventional plasma-fractionation methodology, and administered to another subject in order to impart resistance against or to treat HIV-1 infection. Similarly, monoclonal or polyclonal anti-HIV-1 antibodies produced using a fusion protein according to the present invention can be conjugated to an immunotoxin, as described above, and administered to a subject in whom HIV-1 infection has already occurred but has not become widely spread. To this end, antibody material produced pursuant to the present description would

be administered in a pharmaceutically acceptable carrier, as defined herein.

The present invention is further described below by reference to the following, illustrative examples. In keeping with standard polypeptide nomenclature, the following abbreviations shown below for amino acid residues are used.

TABLE OF CORRESPONDENCE

10	Ala	A	Alanine	Leu	L	Leucine
	Arg	R	Arginine	Lys	K	Lysine
	Asn	N	Asparagine	Met	M	Methionine
	Asp	D	Aspartic acid	Phe	F	Phenylalanine
	Cys	C	Cysteine	Pro	P	Proline
15	Glu	E	Glutamic Acid	Ser	S	Serine
	Gln	Q	Glutamine	Thr	T	Threonine
	Gly	G	Glycine	Trp	W	Tryptophan
	His	H	Histidine	Tyr	Y	Tyrosine
20	Ile	I	Isoleucine	Val	V	Valine

In order to test the level of antibody production elicited by the administration of a polypeptide of the present invention, two different protocols were used. In the first, Rhesus monkeys were immunized with an HIV sequence fused to β -galactosidase, and the antibody titer was measured at various times after immunization.

In the second technique, sequences were identified from SIVmac (Simian Immunodeficiency Virus) env that are equivalent, according to the following criteria, to the sequences set forth in Table 1. SIV peptide sequences on SIVmac env that

appeared in a location similar to that found in the primary sequence of HIV-1 env, which were also hydrophilic and at least about 50% homologous to the sequence to the HIV-1 env peptide, were selected.

5 Of the six epitopes shown in Table 1 below, only three SIVmac env sequences, SIV88, SIV582 and SIV647, satisfied all three criteria. A fourth SIV sequence, SIV500, which showed only about 25% homology to HIV500, was also selected, because this
10 epitope was found to be an immunodominant C-terminal epitope on HIV-1 gp120. SIV500 corresponds to the putative C-terminal SIV gp120 sequence. Like HIV500, it was hydrophilic.

15 Because of the criteria used to correlate HIV and SIV sequences, observation of the antibody response of monkeys immunized with an SIV sequence could be used to assess the antibody response of humans immunized with the corresponding HIV
20 sequence. The four SIV polypeptide sequences selected are shown below.

SIV88:

Asn-Val-Thr-Glu-Ser-Phe-Asp-Ala-Trp-Glu-Asn
(NVTESFDAWEN)

SIV500:

25 Arg-Tyr-Thr-Thr-Gly-Gly-Thr-Ser-Arg-Asn-Lys-Arg
(RYTTGGTSRNKR)

SIV582:

30 Glu-Lys-Tyr-Leu-Glu-Asp-Gln-Ala-Gln-Leu-Asn-Ala-Trp-Gly-Cys-Ala-Phe-Arg-Gln-Val-Cys
(EKYLEDDQAQLNAWGCAFRQVC)

SIV647:

Glu-Glu-Ala-Gln-Ile-Gln-Gln-Glu-Lys-Asn-Met-
Tyr-Glu-Leu-Gln-Lys-Leu-Asn-Ser-Trp-Asp
(EEAQIQQEKNMYELQKLNSWD)

5 Example 1. Production and Purification of
Recombinant Fusion Protein.

From published amino-acid sequences,
hydrophobicity plots of the HIV env encoded proteins
were generated, and five domains were selected, each
manifesting conservation of sequences and a high
10 degree of hydrophilicity, and a high content of
amino acids implicated in the determination of the
secondary structure on a protein, such as cysteine,
aromatic amino acids, proline and glycine.
Sequences rich in hydrophobic residues were avoided,
15 since highly hydrophilic regions are more likely to
be antigenic than are hydrophobic regions. Three
peptides, designated HIV88, HIV475 and HIV500 in
Table 1 below, were selected from the NH₂-terminus
and COOH-terminus of gp120, and two peptides from
20 the NH₂-terminus portion of gp41 (HIV647 and HIV705
in Table 1). Also prepared was a sixth domain
(HIV582 in Table 1) from gp41, combining aspects of
two highly immunodominant sequences. See Wang,
J.J.G., et al., loc. cit.; Gnann, J.W., et al., loc.
25 cit..

Oligonucleotides coding for the HIV amino-
acid sequences depicted in Table 1 were synthesized
on a 381A DNA synthesizer (Applied Biosystems,
Foster City, CA). The sequences of these

oligonucleotides are shown in Figure 1. The oligonucleotides were purified and inserted into plasmid pTZ₂ or a derivative thereof, pTOZ or pTIZ, pursuant to methodology of Shaffermann, A., et al., J. Biol. Chem. 262: 6227-37 (1987), the contents of which are hereby incorporated by reference. These plasmids were designed to accommodate various synthetic oligonucleotides in frame with the NH₂-terminus of β -galactosidase coding sequences, and to be expressed as fusion polypeptide under control of the E. coli trp promoter. See Ausubel, et al. (eds.), loc. cit., chapter 13, the contents of which are hereby incorporated by reference.

The synthetic oligonucleotides coding for HIV88 and HIV500 were cloned between the HindIII and PstI sites of pTOZ; HIV582, HIV647 and HIV705 between the NcoI and HindIII sites of pTOZ and HIV475 between the NdeI and HindIII sites of pTZ₂. Correct constructs were verified by restriction enzyme analysis and DNA sequencing.

Strains of E. coli MC1060, see Casadaban, M.J., et al., " β -galactosidase gene fusions for analyzing gene expression in E. coli and yeast," in 100 METHODS OF ENZYMOLOGY 293-308 (Academic Press, New York), were transformed with the various HIV-pTOZ, HIV-pTIZ or HIV-pTZ₂ plasmids. The recombinant E. coli bacteria were maintained by serial passage on Lauria broth agar plates containing 50 μ g/ml of ampicillin.

The E. coli were induced to express β -galactosidase under conditions described by

Grosfeld, H., et al., loc. cit., and Shaffermann, A., et al., loc. cit.. For scale up, an isolate was serially diluted in Lauria broth and ampicillin and allowed to grow overnight at 37 C with agitation. An inoculum from the overnight culture was transferred to a nutritionally deficient, defined medium (M9 media with limited L-tryptophane) and shaken vigorously at 37 C until an optical density of 3.0 (A_{550}) was achieved.

The cultured bacteria were centrifuged and the supernatant was discarded. The resulting pellet was treated with lysozyme for 30 minutes, and lysed by serial freezing and thawing. The lysate was centrifuged at high speed and the supernatant was recovered.

Recombinant protein of the present invention was precipitated from the lysate using ammonium sulfate. The level of production for each HIV-gal was in range of 2% to 10% of total bacterial proteins. Optimal recovery was found in the 40% cut. The precipitate was resuspended in a Tris buffer containing 2-mercaptoethanol, and dialyzed to remove excess salts. The resulting solution contained approximately 50% pure recombinant protein, mixed with other E. coli proteins of nonrecombinant origin, as characterized by Coomassie blue stained SDS-PAGE gels.

In a conventional manner, recombinant protein of the present invention can be further purified by affinity chromatography, as necessary, by use of a gel matrix upon which is immobilized, as a ligand,

monoclonal antibody against beta-galactosidase. Alternatively, the fusion protein can be purified by high-performance liquid chromatographic ion exchange (DEAE5PW Waters Column), yielding over 98% pure protein. Either method would yield fusion protein with greater than 95% purity.

SIV recombinant fusion proteins were made in a similar manner, with oligonucleotides coding for the equivalent SIV amino-acid sequences being used. These oligonucleotides are shown in Figure 2. Sequences of the SIV envelope are according to those published for SIVmac. See Franchini, G., et al., Nature 328: 539-42 (1987).

Example 2. Evaluation of Reactive Specificity for Selected Domains of HIV Envelope Protein.

As a first step in evaluation of the selected HIV env conserved domains, the reactivity of the six different HIV-gal fusion polypeptides was analyzed with specific panels of HIV-seropositive sera collected from various stages of HIV infection.

Serum samples were collected from patients having two separate serum specimens positive for anti-HIV antibodies by ELISA and western blot. See Redfield, R.R., et al., New Engl. J. Med. 314: 131-32 (1986). Virus-positive samples were defined as those in which a simultaneous culture of the patient's peripheral blood monocytes (PBMCs) yielded a positive culture by either RT activity or antigen capture, according to Gallo, D., et al., J. Clin. Microb. 25: 1291-94 (1987).

5 To assay the sera, an equivalent of 15 ng of
HIV peptides (0.7-1.5 μ g of 98% pure HIV- β -
galactosidase) were dotted in duplicates on
nitrocellulose filter disks. Filters were blocked
with 1% casein/BSA for 2 hours at room temperature
and then incubated for 18 hours at room temperature
with four fold serial dilutions of sera, starting
from a dilution of 1:100. Filters were washed and
10 incubated with goat anti-(IgG, IgM) human antibodies
conjugated to phosphatase (Kirkegaard Perry) at a
final concentration of 3 ng/ml and developed (with
Fast red TR salt and naphthol AS-MX phosphate Sigma)
for 30 minutes. Each filter was dotted with all the
HIV- β gal proteins as well as with a control of β -
15 galactosidase. The end point of titration was
determined by three individuals. Out of a total of
1360 readings of HIV-gal titrations, complete
accordance was achieved in 1350 cases.

20 As shown in Table 1, each of the HIV-derived
peptides were recognized by antibodies elicited in
some or all the HIV-infected individuals. None of
the twenty control sera reacted with the HIV- β gal
polypeptides.

Table 1. Amino Acid Sequence of Various HIV- β -Galactosidase Fusion Proteins and Their Reactivities with HIV Seropositive Sera.

HIV-gal	HIV-Amino Acid Sequence	Number Positive/Total (percent positive)
HIV88	NVTENFNMWKN	32/75 (43)
HIV475	MRDNWRSELYKYKV	8/30 (27)
HIV500	KAKRRVVOREKRAVG	36/75 (48)
HIV582	ERYLKDQQLGIWGCSGKLC	75/75 (100)
HIV647	EESQNQQEKNEQELLELDKWA	25/30 (83)
HIV705	VNRVRQGYSPLSFQT	5/30 (17)

In general, a decrease in titers against the HIV domains tested heretofore has been observed with progression of disease. It is significant as well as unexpected, therefore, that all of the HIV-positive sera not only reacted with HIV582, but also responded in titers (10^{-5}) that were almost two orders of magnitude higher than any of the other conserved envelope regions (see Table 2). By contrast, HIV500, which overlaps most of the sequences of SP22 previously identified as a major immunodominant epitope on gp120 by Parker, T.J., et al., loc. cit., was recognized in only 48% of HIV positive sera and only elicited an antibody titer in the range of 1:1500 in the HIV-infected individual.

The increased magnitude of response is a result of the high level of expression of HIV582 at all stages of infection as compared to other epitopes. This difference in level of expression vis-a-vis other epitopes is especially high during early stages of infection, allowing HIV582 to

successfully detect infection at a much earlier stage than other epitopes. The HIV582 sequence is thus shown to provide a sensitive tool for diagnostic purposes, capable of detecting very early stages of infection.

Table 2. Differential Reactivities of HIV-8gal Polypeptides with Sera from WR Stages 1 & 2 Versus WR Stages 5 & 6.

	HIV-8gal	Positive/Total (%)		Geometric Mean Titer of Positive Specimens	
		WR 1 & 2	WR 5 & 6	WR 1 & 2	WR 5 & 6
	HIV88	29/47* (62)	3/28* (11)	1:780	1:1,260
	HIV475	6/17 (35)	2/13 (15)	1:710	1:200
	HIV500	25/47 (53)	11/28 (39)	1:1,450	1:1,000
	HIV582	47/47 (100)	28/28 (100)	1:140,000	1:78,000
	HIV647	14/17 (82)	11/13 (85)	1:3,600	1:1,550
	HIV705	4/17 (23)	1/13 (8)	1:1,000	1:600

*Difference in proportion positive is statistically significant ($p < 0.00001$ by Fisher Exact test).

Of the two other conserved epitopes in gp41 that have been studied, the one within HIV647 also seems to be immunodominant. HIV647-8gal was recognized by 83% of HIV positive tested sera in any stage of the disease and in relatively high titers, as shown in Table 2. On the other hand, no reaction with HIV-positive sera was observed when a very

similar peptide, CQNQQEKNEQELLE, was used. Gnann, J.W., et al., loc. cit.. This may reflect the presence of the extra amino acids in HIV647, or it may result from the higher sensitivity of the immunodot method used. Alternatively, it may be that the coupling of this peptide to keyhole limpet hemocyanin results in conformational changes not occurring in HIV647- β gal.

Further study was made of an additional 45 sera from patients whose PBMCs were cultured for virus isolation, following Gallo, D., et al., J. Clin. Microbiol. 25: 1291-94 (1987). Within this group studied, twenty patients were virus isolation-negative (all in Walter Reed stages 1 or 2) and twenty-five patients were virus isolation-positive (ten in WR stages 1 or 2, and fifteen in WR stages 5 or 6). Since success of virus isolation is only 10-15% from PBMC specimens from patients in early stage disease, but close to 100% from patients in late stage disease, the sera selected for testing were intentionally biased in favor of virus culture-positive, early-stage patients.

As shown in Table 3, thirteen of the twenty HIV culture-negative patients (65%) had detectable HIV88- β gal reactivity, while only five of twenty-five sera from HIV isolation-positive patients had detectable HIV88- β gal antibodies ($p < 0.003$). Among sera from early-stage patients (WR 1 or 2) only, thirteen of twenty specimens from virus culture-negative patients had HIV88- β gal reactivity, compared to only three of ten virus culture-positive

patients ($p=0.077$). Antibodies to HIV500- β gal and HIV582- β gal were detected equally often in sera from virus isolation-positive and -negative patients. But unlike HIV500, HIV582 was positive in every tested case, regardless of the stage of the disease or the ability to detect virus in PBMC culture.

Table 3. Distribution of Reactivities of HIV- β gal Polypeptides with Selected Sera from Patients with Positive or Negative Virus Isolation from PBMCs.

HIV- β gal	Patient Sera		
	Stage 1-2 Virus Neg	Stage 1-2 Virus Pos	Stage 5-6 Virus Pos
HIV-88	13/20	3/10	2/15
HIV-500	9/20	6/10	4/15
HIV-582	20/20	10/10	15/15

Example 3. Antigenicity of the Recombinant Protein Versus Known Synthetic Peptide Conjugated to Bovine Serum Albumin.

By means of a dot immunoassay, the antigenicity of the fusion protein was found to be far superior to a commercially synthesized peptide (Peninsula, Belmont, CA) which consisted of the same twenty-one amino acids of HIV582 conjugated to bovine serum albumin (BSA). This peptide conjugate was prepared such that BSA and the twenty-one amino acid sequence of HIV582 were present in equivalent weights, i.e., one mg of conjugate contained 500 ng

of HIV582 and 500 ng of BSA. Ammonium sulfate-precipitated recombinant HIV antigen was used at 50% purity, and the weight of the HIV582 was calculated to be 10 ng/mg total protein in the antigen solution. The recombinant and peptide conjugate antigens were prepared as 1 mg/ml total protein solutions (determined by the Lowry method) and 5 μ l samples of serially diluted antigen were applied to nitrocellulose paper, air dried, and blocked. It was confirmed that equivalent amounts of total protein were bound to the nitrocellulose by reaction with ninhydrin. The paper was incubated for four hours with serum containing HIV antibodies diluted 1:100, and antigen-bound antibody was detected with a peroxidase-conjugated secondary antibody system. The results are presented in Table 4, where the intensity of the visible dot was graded on a scale in which +/- was a barely detectable reaction, and ++++ was an intensely dark dot on the nitrocellulose paper. These results indicate that the recombinant HIV582 antigen is at least 50 times more sensitive than the synthetic peptide conjugate that was used in the diagnostic assay.

Table 4. Comparison of Recombinant HIV582- α gal and Synthetic HIV582-BSA Conjugate.

5	Recombinant HIV582- α gal		Synthetic HIV582-BSA	
	Antigen (ng)	Reactivity	Antigen (ng)	Reactivity
	50	++++	2500	++++
	25	++++	1250	++++
	12.5	++++	625	+++
10	6.25	++++	312.5	+++
	3.13	+++	156.25	++
	1.57	+++	78.12	++
	0.78	++	39.10	+
15	0.39	+	19.55	+/-

Example 4. Comparative Study of Fusion Protein-Based Western Blot and Conventional Whole-Virus HIV-1 Western Blot.

20 Western blot strips containing the fusion protein were prepared by SDS-PAGE followed by transfer to nitrocellulose paper. Strips containing approximately 2 μ g of fusion protein were cut from the nitrocellulose strips and used to characterize a pool of 400 sera from HIV-infected patients as determined from clinical symptoms, whole-virus western blot or virus isolation, and 500 HIV-negative sera at 1:100 dilution. All 400 HIV-positive samples reacted with the fusion protein, while none of the 500 negative samples reacted with

25

the antigen. The specificity and sensitivity of the test with this sample population were thus 100%.

A subpopulation of 104 sera from the pool of 400 was characterized using a the conventional whole-virus HIV-1 western blot (DuPont). According to the manufacturer, the presence of antibodies to three specific antigens, gag, env and RT, are required for a positive diagnosis. Many physicians, however, positively diagnose the disease based on the presence of antibodies to only two antigens, env and either gag or RT. The results with the whole-virus western blot are shown in Table 5.

Table 5. Sera Reactivity with Whole-virus Western Blot.

Antigen	Number of Sera
gag, env and RT	84
env and gag or env and RT	11
env only	4
gag only	4
no reaction	1

Thus, even under the more relaxed "two out of three" criteria, the conventional whole-virus western blot gives a false negative in over 8% of the samples. Most importantly, the whole virus failed to identify one of the sera as positive under any criteria. This individual was later identified

as HIV positive when results of his virus isolation were complete.

5 The diagnostic assay based on HIV582 correctly identified all 104 infected individuals. Thus, the HIV582 assay identifies infected individuals that do not give a positive reaction with any of the three antigens used in whole virus western blot assay, allowing HIV positive individuals to be identified at an earlier stage of infection.

10

Example 5. Antibody titers to various SIVmac env peptides in plasma from different macaque species infected with SIVMne.

15 Three juvenile Rhesus macaques (M. mulatta), three juvenile pigtailed macaques (M. nemestrina), and two cynomolgus macaques (M. fascicularis) were inoculated intravenously with 10^3 TCID of SIV/Mne. See Shaffermann, A., et al., J. Aids Res. 5: 327-26 (1989), the contents of which are incorporated herein by reference. All macaques became viremic within three weeks after inoculation, and all mounted an antibody response to SIV/Mne except M. nemestrina T85056, which died at fifteen weeks with an ulcerative necrotizing colitis and a marked decrease in CD4+ PBL. The other macaques died 43-20 121 weeks after inoculation after exhibiting progressive weight loss, anemia, and diarrhea. Histopathologic findings at necropsy included various manifestations of immune deficiency.

25

The development of antibodies of SIV/Mne was determined by estern immunoblotting at various times after inoculation, and is tabulated in Table 5. Seven macaques developed readily detectable antibodies by 5-6 weeks after inoculation, with antibodies to gag p28 and to the transmembrane protein p34E generally appearing before antibodies to other gene products was detected. At various times after inoculation, antibodies to gp120 (the envelope protein) and to gag proteins p16, p8 and p6 were also evident. In addition, some of the macaques developed antibodies to p14, which has been identified as the product of the X-orf gene of SIV.

Prior to inoculation of monkeys with SIV/Mne, none of the primate sera (dilution 1:100) reacted with the SIVmac env-gal polypeptides, yet all SIVmac env- β gal polypeptides reacted with antibodies elicited in all the post-SIV/Mne infected monkeys. Pig-tailed macaque T85056, although viremic, remained antibody-negative after inoculation. Plasma from this animal did not react with the SIVmac env- β gal polypeptides. The order of both antibody prevalence to the various SIV env epitopes and the immunogenicity of these epitopes in SIV-infected macaques is SIV-582 \geq SIV-647 > SIV-500 > SIV-88. The order of antibody prevalence and of immunogenicity of these envelope epitopes is identical to that found for the equivalent HIV envelope epitopes in humans infected with HIV-1.

The results show that the humoral response in macaques infected with SIVMne to the specific SIVmac

envelope epitopes parallels that observed for the equivalent HIV env epitopes in humans infected with HIV. This shows that the SIV macaque system is a suitable model for assessing HIV vaccines and other immunotherapies for AIDS.

5

Table 5. Antibody response to SIVmac env peptides from macaques infected with SIVMne.

Animals infected with SIVMne.							
5	Animal	Weeks after infection	Antibody titer				
			SIV88	SIV500	SIV582	SIV647	
10	<u>M. mulatta</u>						
15	A85033	9	<1:100	<1:100	1:6400	<1:100	
		36	<1:100	1:200	1:100K	<1:100	
		66	<1:100	<1:100	1:100K	1:400	
	A85034	14	<1:100	<1:100	1:25K	<1:200	
		36	<1:100	<1:100	1:50K	1:1600	
		87	<1:100	<1:100	1:200K	1:6400	
	A85037	14	<1:100	1:400	1:1600	<1:100	
		36	<1:100	1:1600	1:25K	<1:100	
		95	<1:100	1:1600	1:6400	1:100	
20	<u>M. nemestrina</u>						
25	F85062	18	<1:100	1:400	1:100K	1:600	
		36	1:400	1:400	1:400K	1:1600	
		80	<1:100	1:400	1:100K	1:1600	
	M85026	18	1:400	<1:100	1:25K	1:6400	
		66	1:400	<1:100	1:100K	1:100K	
		120	1:200	<1:100	1:100K	1:400K	
	<u>M. fascicularis</u>						
	30	85175	12	1:100	1:100	1:6400	1:100
			37	1:100	1:100	1:12,500	<1:100
51			1:400	<1:100	1:50K	<1:100	
85176		12	1:200	1:1600	1:25K	1:200	
		24	1:400	1:3200	1:100K	1:400	
		43	1:200	1:6400	1:100K	1:400	

* Plasma from all macaques were seronegative for all SIV env-gal polypeptides at a dilution of 1:100 prior to inoculation with SIVMne.

Example 6. Immunization of M. mulatta with HIV647- β gal.

Three groups of monkeys (3 animals/group) were immunized with different doses of HIV647- β gal: 4, 40 and 400 μ g (95% HPLC pure). On day zero, each animal received complete Freund's, on day 14 each animal received incomplete Freund's, and on day 35 each animal received soluble antigen only. Adjuvant was mixed (0.5 ml with 0.5 ml HIV- β gal prior to inoculation. Monkeys were inoculated intramuscularly at four sites with 0.25 ml per site.

The antibody response was measured by an immunodot test in which 1.0 μ g of 98% pure antigen (HIV647- β gal, HIV88- β gal and β gal) was dotted in duplicate on nitrocellulose filters. The filters were blocked with 1% casein/BSA for two hours. Diluted sera were preincubated with β gal, at concentrations of 200-80 μ g/ml, for one hour at 37°C and then incubated for eighteen hours at room temperature with the filters. Filters were washed, then incubated with goat anti-human phosphatase antibodies (3 ng/ml) for three hours and developed for nine minutes.

An ELISA was also performed with a synthetic twenty amino acid peptide of the HIV647 epitope. ELISA was performed on PVC plates preincubated with 4 μ g/ml of a cys-647 HIV peptide, a synthetic peptide of HIV647 to which a cysteine residue was added at the N-terminus. Linearity of OD readings with sera dilution was not observed. Differential (Day x-Day zero) OD values for each dilution were

used to determine the endpoint. A significant differential OD value was considered to be that which was threefold higher than that obtained from the differential value of Day 14-Day Zero and above a cutoff value of 0.040. No attempt was made to optimize the sensitivity of the ELISA.

On day zero, no sera had detectable antibody to HIV647 at a serum dilution of 1:100 with immunodot or 1:8 with ELISA. On day 14, all sera had titers lower than 1:1000. None of the sera reacted with a control of HIV88- β gal. The antibody titers on days 28 and 51 as measured by both immunodot and ELISA are shown in Table 7.

Table 6. Antibody response to HIV647- β gal measured by immunodots and ELISA.

Dose	Animal	Immunodot Titer		ELISA titer	
		Day 28	Day 51	Day 28	Day 51
4	T313	1:2000	1:64K	<1:8	1:256
4	O27A	1:16K	1:64K	1:512	1:1024
4	T324	<1:1000	1:32K	<1:8	1:1024
40	O5	1:4000	1:32K	<1:8	<1:8
40	X662	1:16K	1:64K	1:64	1:128
40	T308	n.m.	n.m.	1:128	1:128
400	T34	1:16K	1:32K	1:32	1:128
400	P792	1:8000	1:16K	1:16	1:128
400	A32	1:2000	1:64K	<1:8	1:128

n.m. - not measurable due to β gal background

The fact that the sera reacted with HIV647- β gal, but not with HIV88- β gal, indicates that the response

is specific to HIV647. The ELISA results confirm that, while HIV647- β gal is composed of both HIV647 and β gal, antibodies are produced against the HIV647 sequence.

5 The antibody response to the β gal immunocarrier was also measured by immunodot titration. All sera on day zero had anti- β gal titers lower than 1:50. The results on days 14, 28 and 51 are shown in Table 7.

10 Table 7. Antibody response to the β gal immunocarrier.

Dose	Animal	Immunodot Titer		
		Day 14	Day 28	Day 51
4	T313	<1:500	1:50K	1:250K
4	O27A	<1:500	1:50K	500K
4	T324	<1:500	1:500	1:25K
40	O5	1:5000	1:50K	1:50K
40	X662	1:5000	1:250K	1:250K
40	T308	1:500	1:50K	1:50K
400	T34	1:500	1:250K	1:250K
25	P792	1:25K	1:50K	1:100K
400	A32	1:5000	1:25K	1:250K

30 The HIV647- β gal elicited antibodies that recognized specifically not only HIV647- β gal, but also the twenty-two amino acid HIV647 peptide. The results show that the HIV647 epitope is very immunogenic and β gal is a potent immunocarrier in monkeys. Specific immune response to the HIV647 epitope was obtained when as little as 4 μ g of the

fusion protein, equivalent to only 80 ng of the HIV sequence, is used. In immunodots the titer of anti-HIV647 antibodies was 1:64000, which was only fivefold lower than the titer obtained against the large (400,000-dalton) β gal tetramer.

No suppression of the immune response was observed when 4 to 400 μ g was used. Titers to β gal reached a level of 1:250000, independent of the dose. The boost with soluble antigen was most significant at the lowest dose. Also, a somewhat higher anti-HIV647 antibody titer was obtained at the lowest dose of β gal.

Example 7. Immunization of HIV647- β gal preimmunized M. mulatta with HIV582- β gal.

Three Rhesus monkeys from Example 6, T313, O27A and T324, were immunized with 4 μ g of HIV582- β gal, according to the protocol of Example 6. The antibody titers to both HIV647- β gal and HIV582- β gal as measured by immunodot are shown in Table 8.

Table 8. Antibody response HIV647- β gal and HIV582- β gal.

Animal	HIV647- β gal Titer			HIV582- β gal titer	
	Day 51	Day 147*	Day 190	Day 147*	Day 190
T313	1:64K	1:16K	1:16K	<1:100	1:8000
O27A	1:64K	1:8000	>1:16K	<1:100	>1:16K
T324	1:32K	1:1000	1:2000	<1:100	1:1000

* Day 147 is day 0 for immunization with HIV582- β gal

The results show that HIV582 is also an immunogenic epitope in Rhesus monkeys. Preimmunization with HIV647- β gal did not prevent effective immunization with HIV582- β gal. The moderate increase in HIV647 titer indicates that the use of the same immunocarrier in consecutive immunizations of two different HIV epitopes helps memory cells generated from the first immunization.

Example 8. Immunization of M. mulatta with SIV- β gal fusion proteins.

Three groups of monkeys (3 animals/group), free of antibodies to both HIV and SIV, were used. Each group was immunized according to the protocol of Example 6. In each case 4 μ g of antigen was used in the immunization. One group (animal 3X7, 4GP and 4GI) was immunized with a mixture of the four different SIV- β gal polypeptides (SIV88, SIV500, SIV582 and SIV647). A second group was immunized with SIV647- β gal (4GN, 4GJ and 4GG) and a third group was immunized with β gal. As in Example 6, antibody titers were determined with both immunodot and ELISA. ELISA was performed as described in Example 6, except that plates were coated with synthetic SIV peptides conjugated to BSA.

On day zero and day 14, no sera had detectable antibodies to any SIV epitope at a serum dilution of 1:100. On day 36, all titers were one-quarter to one-half the values on day 43, which are reported in Table 9. The antibody response to β gal is reported in Table 10.

44

Table 9. Antibody response to SIV epitopes in M. mulatta on day 43.

	Animal	Assay	SIV88	SIV500	SIV582	SIV647
5	3X7	Immunodot ELISA	1:256K 1:16	1:64K	1:128K 1:512	1:256K 1:1024
10	4GP	Immunodot ELISA	1:256K 1:256	1:64K	1:64K 1:1024	<1:256K 1:512
	4GI	Immunodot ELISA	1:64K 1:256	1:16K	1:32K > 1:1024	1:256K 1:256
	4GN	Immunodot ELISA	--	--	--	1:128K 1:1024
15	4GJ	Immunodot ELISA	--	--	--	1:256K > 1:1024
	4GG	Immunodot ELISA	--	--	--	1:256K 1:128

Table 10. Antibody response to the β gal immunocarrier.

	Animal	Immunodot Titer			
		Day 0	Day 14	Day 36	Day 43
25	3X7	<1:100	1:1000	1:400K	\geq 1:400K
	4GP	<1:100	1:100	1:200K	\geq 1:400K
30	4GI	<1:100	1:25K	1:400K	\geq 1:400K

The results demonstrate that all four SIV epitopes are immunogenic in Rhesus monkeys when

presented as β gal fusion proteins. The immunodot and ELISA results show that antibodies were directed exclusively against the SIV moiety of the SIV- β gal. The ability of the anti-SIV- β gal monkey antibodies to react with SIVmne antigens was tested in western blots of whole disrupted virus and with ^{35}S -methionine labelled SIVmne cell lysates in a RIP assay. It was found that the anti-SIV- β gal antibodies reacted with both the transmembrane (p32) and the envelope (gp110) of SIV. These results clearly demonstrate that presentation of SIV epitopes via β gal can elicit an immune response which mimics that of native virus antigens. However, none of the immune sera had any neutralizing activity against SIV virus in vitro.

The antibody titers for all SIV antigens ranged from 1:16000 to 1:256000. Considering that the SIV epitope constitutes only 1-2% of the molecular weight of the β gal immunocarrier, the titer level is exceptionally high. Antibody titers to the immunocarrier are approximately 1:400000.

The natural antibody response in monkeys infected with SIVmne are:

SIV88	<1:100-1:400
SIV500	1:100-1:1600
SIV582	1:25000-1:400000
SIV647	1:400-1:6400

Thus, with the exception of SIV582, the immunization with all SIV- β gal tested elicited an antibody response 10-100 fold higher than that elicited against these epitopes by the virus itself.

Immunization with a combination of all four SIV- β gal fusion proteins did not produce antigenic competition. The level of specific antibodies to SIV647 was comparable when immunization was with SIV647- β gal alone or in combination with other fusion proteins.

Example 9. Challenge of SIV- β gal immunized M. mulatta with SIVmne.

The three monkeys immunized with the combination of all four SIV- β gal fusion proteins (3X7, 4GI and 4GP) were boosted at day 290. The boost was performed with soluble antigen. Each monkey received 40 μ g of each of the SIV- β gal peptides by intramuscular injection.

Twenty-one days after the boost, the monkeys were challenged with viable SIV. All three immunized monkeys developed serologic evidence of transient SIV infection, whereas all three control monkeys developed positive western blots to numerous viral antigens, had reverse transcriptase activity detectable in their sera on repeated occasions, and were positive for viral nucleic acid sequences, indicating the presence of ongoing SIV infection. The results are summarized in Table 11.

47

Table 11. Results of reverse transcriptase and western blot assays on sera of monkeys challenged with SIVmne.

Day	Immunized monkeys								Control Monkeys			
	3X7	4GI	4GP	4GC	4HS	3XP						
	RT	WB	RT	WB	RT	WB	RT	WB	RT	WB	RT	WB
10	-6
	0
	7
	14	.	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
	21	.	.	+(2)
15	27	.	+
	41	.	±(1)	++(2)+	++(3)-	+	++(3)
	55	.	.	.	+	+	.
	64	.	.	++(4)-	±(3)	+	+++ (4)	.	++(4)nd	.	+	++(3)
20	94	.	+

Day zero = SIVmne challenge day

RT - Cocultivation-Reverse Transcriptase assay

WB - Western blot performed on SIVmne partially purified lysate

- 25
- (1) env p32
 - (2) env p32 and p28
 - (3) env p32 and gp110 as well as p28
 - (4) env p32 and gp110 as well as p28 and p16

30 One of the three immunized monkeys (3X7) never became virus positive and two were transiently positive. Unlike the controls, none of the three experimentally vaccinated animals showed evidence of infection (by RT) 55 days post challenge. Two of the three developed a booster response against only the antigens with which they were immunized,

35 demonstrating that post-vaccination exposure to the virus was capable of inducing an anamnestic booster response to the vaccine.

The antibody titer for the monkeys was determined by ELISA. All samples were run in duplicate at a 1:400 dilution and read on a V_{\max} ELISA reader at 850 nm. The results, expressed as MOD/min by a kinetic read, are summarized in Table 12.

Table 12. Antibody titer of monkeys challenged with SIVmne.

Animal	Days post challenge with SIVmne									
	1	14	21	28	41	55	84	118	148	174
4GI	1.7	1.1	nd	10	9.2	8.0	6.4	7.1	5.8	5.8
4GP	0.1	0.1	nd	0.9	6.0	0.8	1.1	1.7	1.8	1.6
3X7	0.2	0.2	nd	6.5	5.2	2.9	1.0	1.0	1.0	0.7
4GC	0.1	0.1	0.6	3.1	1.4	8.6	15	12	13	14
4HS	0.1	0.1	0.6	2.4	5.2	6.8	8.5	8.8	10	11
3XP	0.1	0.1	1.0	3.4	6.0	7.1	12	12	20	23

In all the monkeys there was an increase in antibody titer (crossreacting with HIV-2). In immunized monkeys, antibody level decreased between day 28 and day 41 in 3X7, between day 41 and day 55 in 4GP, and between day 118 and day 146 in 4GI. In control monkeys, there is a progressive increase in antibody level. The decline in antibody level indicated again that in monkeys immunized by SIV-Bgal, SIV is being eliminated.

The protection of vaccinated monkeys against infection was quite surprising in view of the fact that SIV-Bgal did not induce neutralizing antibodies in vitro. This finding is consistent with the

clinical observation that actively infected and ill
AIDS patients have high levels of such neutralizing
antibodies. The highly conserved antigenic
sequences result in antibodies that are not
5 neutralizing in vitro but are protective in vivo.
Because the absolute level of antibody does not
exhibit a straightforward correlation with
protection against SIV infection, it is possible
that cellular immune responses may be induced by
10 these vaccine constructs and may play an important
role in protection against SIV infection in vivo.

What is Claimed Is:

1. A fusion protein comprised of:
an amino acid sequence selected from the group consisting of NVTENFNMWKN, KAKRRVVQREKRAVG, ERYLKDQQLLGIWGCSGKLIC and EESQNQQEKNEQEELLELDKWA; and
a non-HIV polypeptide sequence,
such that said amino-acid sequence and said polypeptide sequence comprise the backbone of said fusion protein, wherein said fusion protein reacts with an HIV-positive serum.
2. A fusion protein according to Claim 1, wherein said amino-acid sequence is joined via a peptide bond to an N-terminus of said polypeptide sequence.
3. A fusion protein according to Claim 2, wherein said polypeptide sequence comprises the sequence of β -galactosidase.
4. A self-replicating cell that expresses a polypeptide comprising an amino-acid sequence selected from the group consisting of NVTENFNMWKN, KAKRRVVQREKRAVG, ERYLKDQQLLGIWGCSGKLIC and EESQNQQEKNEQEELLELDKWA.

5. A diagnostic assay for detecting the presence of anti-HIV antibody in a sample, comprising the steps of:

(A) immobilizing on a solid matrix a fusion protein comprising an amino-acid sequence ERYLKDQQLLGIWGCSGKLIC and a non-HIV polypeptide sequence, such that said amino-acid sequence is accessible to an antibody contacting a surface of said matrix;

(B) bringing a sample into contact with said surface of said matrix; and

(C) monitoring said surface for binding of HIV-specific antibody.

6. A diagnostic assay according to claim 5, wherein step (C) comprises detecting the presence of anti-HIV antibody in a sample that tests HIV-negative when tested using a conventional whole-virus western blot assay.

7. A diagnostic assay for detecting the presence of anti-HIV antibody in a sample, comprising the steps of:

(A) providing a fusion protein comprising an amino-acid sequence ERYLKDQQLLGIWGCSGKLIC and an amino acid sequence of an enzyme;

(B) combining a sample with the fusion protein in a liquid; and

(C) monitoring the combination for a modulation of activity of the enzyme.

8. A vaccine comprising a fusion protein according to Claim 1 and a sterile, pharmaceutically acceptable carrier therefor.

9. An immunotherapy method comprising the step of administering to a subject an immunostimulatory amount of a vaccine according to Claim 8.

10. An immunotherapy method according to Claim 9, wherein subject is already infected with HIV-1 when said vaccine is administered.

11. A method of preparing an immunotherapeutic agent against HIV infection, comprising the step of immunizing a plasma donor with a vaccine according to Claim 8 such that a hyperimmune globulin is produced which contains antibodies directed against HIV-1.

12. An immunotherapy method comprising the step of administering to a subject an immunostimulatory amount of a hyperimmune globulin prepared according to Claim 11.

13. An immunotherapy method comprising the step of administering to a subject, said subject being infected with HIV-1, antibodies directed against a fusion protein according to Claim 1, wherein said antibodies are conjugated to an immunotoxin.

14. An immunotoxin conjugate comprising a fusion protein according to Claim 1 conjugated to an immunotoxin.

15. A composition consisting essentially of antibodies that bind a fusion protein according to Claim 1.

16. A composition according to Claim 15, wherein said composition is a monoclonal antibody composition.

17. A composition according to Claim 15, wherein said antibodies are not obtained by a process comprising the step of providing a biological sample from a human subject infected with HIV-1.

1/4

FIGURE 1A

HIV88

HindIII

AGCTT	Asn	Val	Thr	Glu	Asn	Phe	Asn	Met	Trp
A	AAC	GTA	ACT	GAA	AAC	TTC	AAC	ATG	TGG
	TTG	CAT	TGA	CTT	TTG	AAG	TTG	TAC	ACC

Lys	Asn	
AAA	AAC	CTGCA
TTT	TTG	G

PstI

FIGURE 1B

HIV500

HindIII

AGCTT	Lys	Ala	Lys	Arg	Arg	Val	Val	Gln	Arg
A	AAA	GCT	AAA	CGT	CGT	GTA	GTA	CAG	CGT
	TTT	CGA	TTT	GCA	GCA	CAT	CAT	GTC	GCA

Glu	Lys	Arg	Ala	Val	Gly	
GAA	AAG	CGC	GCT	GTA	GGT	CTGCA
CTT	TTC	GCG	CGA	CAT	CCA	G
						PstI

2/4
FIGURE 1C

HIV582

NcoI

CATG	Glu GAA CTT	Arg CGT GCA	Tyr TAC ATG	Leu CTG GAC	Lys AAA TTT	Asp GAC CTG	Gln CAG GTC	Ala CAG GTC	
Leu CTG GAC	Leu CTG GAC	Gly GGT CCA	Ile ATC TAG	Trp TGG ACC	Gly GGT CCA	Cys TGT ACA	Ser TCT AGA	Gly GGT CCA	Lys AAA TTT
Leu CTG GAC	Ile ATC TAG	Cys TGC ACG	A TTCGA HindIII						

FIGURE 1D

HIV647

NcoI

CATG	Glu GAA CTT	Glu GAA CTT	Ser TCT AGA	Gln CAG GTC	Asn AAC TTG	Gln CAG GTC	Gln CAG GTC	Glu GAA CTT	Lys AAA TTT
Asn AAC TTG	Glu GAA CTT	Gln CAG GTC	Glu GAA CTT	Leu CTT GAA	Leu CTG GAC	Glu GAG CTC	Leu CTC GAG	Asp GAC CTG	Lys AAA TTT
Trp TGG ACC	Ala GCT CGA	A TTCGA HindIII							

3/4

FIGURE 2A

SIV88

HindIII

AGCTT	Asn	Val	Thr	Glu	Ser	Phe	Asp	Ala
A	AAC	GTA	ACT	GAA	TCT	TTC	GAC	GCT
	TTG	CAT	TGA	CTT	AGA	AAG	CTG	CGA

Trp	Glu	Asn	
TGG	GAA	AAC	CTGCA
ACC	CTT	TTG	G

PstI

FIGURE 2B

SIV500

HindIII

AGCTT	Arg	Tyr	Thr	Thr	Gly	Gly	Thr	Ser
A	CGT	TAC	ACT	ACT	GGT	GGT	ACT	TCT
	GCA	ATG	TGA	TGA	CCA	CCA	TGA	AGA

Arg	Asn	Lys	Arg	
CGT	AAC	AAA	CGT	CTGCA
GCA	TTG	TTT	GCA	G

PstI

4 / 4

FIGURE 2C

SIV582

NcoI

CATG	Glu GAA CTT	Lys AAG TTC	Tyr TAC ATG	Leu CTG GAC	Glu GAA CTT	Asp GAC CTG	Gln CAG GTC	Ala GCT CGA		
Gln CAG GTC	Leu CTG GAC	Asn AAC TTG	Ala GCT CGA	Trp TGG ACC	Gly GGT CCA	Cys TGC ACG	Ala GCT CGA	Phe TTC AAG	Arg CGT GCA	
Gln CAG GTC	Val GTT CAA	Cys TGT ACA	A TTCGA							

Hind III

FIGURE 2D

SIV647

NcoI

CATG	Glu GAA CTT	Glu GAA CTT	Ala GCT CGA	Gln CAG GTC	Ile ATC TAG	Gln CAG GTC	Gln CAG GTC	Glu GAA CTT		
Lys AAG TTC	Asn AAC TTG	Met ATG TAC	Tyr TAC ATG	Glu GAA CTT	Leu CTG GAC	Gln CAG GTC	Lys AAA TTT	Leu CTG GAC	Asn AAC TTG	
Ser AGC TCG	Trp TGG ACC	Asp GAC CTG	A TTCGA							

HindIII

THIS PAGE BLANK (USPTO)